PMID- 19175715
OWN - NLM
STAT- MEDLINE
DCOM- 20090415
LR  - 20161018
IS  - 0891-6640 (Print)
IS  - 0891-6640 (Linking)
VI  - 23
IP  - 1
DP  - 2009 Jan-Feb
TI  - Fluorescence in situ hybridization confirms clearance of visible Helicobacter 
      spp. associated with gastritis in dogs and cats.
PG  - 16-23
LID - 10.1111/j.1939-1676.2008.0211.x [doi]
AB  - BACKGROUND: The results of studies examining the role of Helicobacter spp. in the 
      pathogenesis of canine and feline gastritis are inconclusive. Furthermore, data 
      evaluating the effectiveness of medical therapy for eradication of Helicobacter 
      infection are limited. AIM: To detect Helicobacter spp. in mucosal biopsies of 
      dogs and cats diagnosed with gastritis, with fluorescence in situ hybridization 
      (FISH). ANIMALS: Three dogs and 2 cats with signs of chronic gastrointestinal 
      disease. METHODS: Dogs and cats infected with Helicobacter spp. were treated with 
      triple antimicrobial therapy and fed an elimination diet for 21 days. 
      Helicobacter spp. status in endoscopic (3 dogs, 1 cat) or surgical biopsies (1 
      cat) of gastric mucosa was compared pre- and posttreatment in each animal by 
      histology, FISH analysis, and polymerase chain reaction (PCR). RESULTS: Gastritis 
      of varying severity with intraglandular spiral bacteria was observed in all 
      animals. Pretreatment diagnostic tests confirmed the presence of mucosal 
      Helicobacter spp. in all animals by FISH and histopathology and in 4/5 animals by 
      PCR. Rapid resolution of vomiting episodes was observed in all animals. Gastric 
      biopsies performed after triple therapy revealed clearance of visible 
      Helicobacter spp. by histopathology and negative FISH analysis, as well as PCR in 
      all animals. CONCLUSIONS AND CLINICAL IMPORTANCE: Application of FISH to routine 
      biopsy specimens enabled rapid and specific identification of Helicobacter spp. 
      within the gastric mucosa of dogs and cats. Although medical therapy was useful 
      in resolution of clinical signs and clearance of visible Helicobacter spp. in 
      gastric biopsies, gastric inflammation persisted.
FAU - Jergens, A E
AU  - Jergens AE
AD  - Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa 
      State University, Ames, IA, USA. ajergens@iastate.edu
FAU - Pressel, M
AU  - Pressel M
FAU - Crandell, J
AU  - Crandell J
FAU - Morrison, J A
AU  - Morrison JA
FAU - Sorden, S D
AU  - Sorden SD
FAU - Haynes, J
AU  - Haynes J
FAU - Craven, M
AU  - Craven M
FAU - Baumgart, M
AU  - Baumgart M
FAU - Simpson, K W
AU  - Simpson KW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Vet Intern Med
JT  - Journal of veterinary internal medicine
JID - 8708660
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Organometallic Compounds)
RN  - 0 (Salicylates)
RN  - 140QMO216E (Metronidazole)
RN  - 62TEY51RR1 (bismuth subsalicylate)
RN  - 804826J2HU (Amoxicillin)
RN  - U015TT5I8H (Bismuth)
SB  - IM
EIN - J Vet Intern Med. 2009 Mar-Apr;23(2):443
MH  - Amoxicillin/administration & dosage/therapeutic use
MH  - Animals
MH  - Anti-Bacterial Agents/administration & dosage/*therapeutic use
MH  - Bismuth/administration & dosage/therapeutic use
MH  - Cat Diseases/drug therapy/*microbiology
MH  - Cats
MH  - Dog Diseases/drug therapy/*microbiology
MH  - Dogs
MH  - Drug Therapy, Combination
MH  - Gastritis/drug therapy/*veterinary
MH  - Helicobacter Infections/*veterinary
MH  - In Situ Hybridization, Fluorescence/veterinary
MH  - Metronidazole/administration & dosage/therapeutic use
MH  - Organometallic Compounds/administration & dosage/therapeutic use
MH  - Salicylates/administration & dosage/therapeutic use
EDAT- 2009/01/30 09:00
MHDA- 2009/04/16 09:00
CRDT- 2009/01/30 09:00
PHST- 2009/01/30 09:00 [entrez]
PHST- 2009/01/30 09:00 [pubmed]
PHST- 2009/04/16 09:00 [medline]
AID - JVIM211 [pii]
AID - 10.1111/j.1939-1676.2008.0211.x [doi]
PST - ppublish
SO  - J Vet Intern Med. 2009 Jan-Feb;23(1):16-23. doi: 10.1111/j.1939-1676.2008.0211.x.